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ABSTRACT Thalassemias are hereditary anemias caused
by mutations that disturb the normal 1:1 balance of a- and
3-globin chains that form hemoglobin. We have disrupted the
major adult 3-globin gene (bl) in mouse embryonic stem cells
by using homologous recombination to insert selectable se-
quences into the gene. Mice homozygous for this insertional
disruption of the bl gene (Hbb"l-2/HbbI-2) are severely anemic
and die perinatally. In contrast, -60% ofmice homozygous for
deletion of the same gene (Hbbl*-1/Hbbl*-1) survive to adult-
hood and are much less anemic [Skow, L. C., Burkhart, B. A.,
Johnson, F. M., Popp, R. A., Goldberg, S. Z., Anderson,
W. F., Barnett, L. B. & Lewis, S. E. (1983) Cell 34, 1043-
1052]. These different phenotypes have implications for the
control of ,-globin gene expression.
The a- and (3-globin polypeptide chains of hemoglobin are
encoded by multigene clusters that are generally conserved
throughout mammalian evolution. Within the clusters, the
individual genes are regulated in both a temporal and tissue-
specific manner. There are five functional genes in the human
/3-globin gene cluster: E, an embryonic globin gene expressed
primarily in yolk sac-derived cells from 3 to 8 weeks of
gestation; Gy and Ay, fetal globin genes expressed primarily
in fetal liver-derived cells from 6 weeks of gestation to -3 mo
after birth; and 8 and 3, adult globin genes expressed pri-
marily in bone marrow-derived cells starting shortly before
birth and persisting throughout adult life. The ,3 gene is
responsible for 97-98% of adult 8-globin, and the 8 gene is
responsible for -2-3%. There are four functional genes in the
mouse 3-globin gene cluster: bhl, an early embryonic globin
gene expressed primarily in yolk sac-derived cells from 9.5 to
12.5 days of gestation; y, a late embryonic globin gene
expressed primarily in fetal liver-derived cells from 11.5 to
16.5 days of gestation; and bi (fImaJir) and b2 (fBminor), adult
globin genes first expressed at 9.5 days of gestation in yolk
sac-derived cells, then expressed in fetal liver-derived cells,
then expressed in spleen, and finally expressed in bone
marrow-derived cells throughout adult life (1). The bl gene is
responsible for =80% of adult /3-globin, and b2 is responsible
for -20% (2). The net synthesis of a- and 8-type globin
polypeptide chains is normally balanced at 1:1.
As a step toward generating mice unable to synthesize any
mouse adult f3globins, we have used homologous recombi-
nation in embryonic stem (ES) cells to disrupt the mouse
major adult 3-globin gene (bi) by inserting into its second
exon a bacterial gene (neo) that confers resistance to the drug
G418. Mice homozygous for this insertional disruption of the
bi gene die perinatally due to severe anemia. This
thalassemic phenotype is much more severe than expected
because mice homozygous for deletion of the same gene can
survive (3). We propose a model suggesting how the differ-
ences in the two phenotypes can be explained based on
competition of genes in the globin cluster for interaction with
the locus control region (LCR) (4-7) and for translational
factors.
MATERIALS AND METHODS
Cells and Electroporation. Gene targeting was done with
E14TG2a ES cells isolated from inbred strain 129 mice (8).
The cells were cultured on embryonic fibroblast feeder layers
in Dulbecco's modified Eagle's medium (DMEM)/15% fetal
bovine serum/0.1 mM 2-mercaptoethanol/2 mM glutamine.
The targeting plasmid (see Fig. 1B) was introduced into the
ES cells by electroporation by discharging a 200-IF capacitor
charged to 300 V through a 5-mm-long chamber with a
100-mm2 cross-section. Cells (2 x 107) were used with aDNA
concentration of 5 nM. After electroporation, cells were
cultured at a density of either 5 x 106 or 2 x 106 on 100-mm-
diameter dishes and were exposed to 200mg ofG418 (GIBCO)
per ml and 2 mM ganciclovir (Syntex, Palo Alto, CA).
Screening for Homologous Recombinants. One portion of
each colony surviving exposure to the two drugs was sub-
cultured; another was pooled with five other colonies and
analyzed by PCR as described (9), except that 0.5 p.g ofDNA
and 1 unit of Taq DNA polymerase were used in each
reaction. The PCR mixtures were amplified for 35 cycles with
45 sec of denaturing at 92°C followed by annealing and
extension at 65°C for 10 min. One primer, 5'-GCTAACCA-
GATTTGTGAGCTCAGGG-3', was specific for sequences
in the target gene bl, and the other, 5'-TGGCGGACCGC-
TATCAGGAC-3', was specific for sequences in the neo
gene. After PCR, 20 A1l of the reaction mixture was electro-
phoresed on an agarose gel, transferred to nylon membranes,
and hybridized to a 32P-labeled bl-specific probe (see Fig.
1C) designed to detect a 1.6-kb band expected when these
two primers are used to amplify DNA from a correctly
targeted cell. Three pools gave a positive PCR signal. Indi-
vidual colonies from these pools were then tested by PCR,
and the positive colonies so identified were further analyzed
by Southern blots of digested genomic DNA.
Preparation of Blood. Blood from weanling mice, or day
18.5 embryos, was collected in heparinized hematocrit tubes.
Blood smears made for some animals were stained in
Wright's stain. For other animals, the tubes were sealed and
centrifuged, and hematocrits were measured; the resulting
packed red blood cells were then removed, washed once with
phosphate-buffered saline, and lysed in cystamine-containing
buffer as described (10). Samples containing approximately
equal amounts of hemoglobin were electrophoresed on cel-
lulose acetate membranes (Helena Laboratories).
Abbreviations: LCR, locus control region; neo, neomycin; tk, thy-
midine kinase; ES, embryonic stem.
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RESULTS AND DISCUSSION
Gene Targeting. The targeting plasmid and gene targeting
scheme are illustrated in Fig. 1. The plasmid contains 6.2 kb
of DNA, from a strain BALB/c mouse, that is homologous
to the bi locus. A 1.1-kb fragment from pMClPOLA (Strat-
agene) capable of conferring resistance to G418 is inserted at
a BamHI site in exon 2 of the bl gene. The homologous
segments were 0.8 kb on the 5' side and 5.4 kb on the 3' side
ofthe neo gene. Copies ofthe thymidine kinase (tk) gene from
herpes simplex virus 1 are inserted both 5' and 3' of the
homologous segments so that positive-negative selection
could be used (11). After electroporation with the linearized
targeting plasmid, 144 colonies were picked from a total of
604 that were resistant to both G418 and ganciclovir. PCR
tests of these colonies indicated that three of the 144 colonies
were correctly targeted. This number corresponds to a fre-
quency of one targeted colony for every 1.5 x 106 starting
cells. The selection with ganciclovir reduced the number of
surviving cells to about one-tenth of those surviving with
G418 alone.
The three independently targeted cell lines identified by
PCR were confirmed by Southern blots of digested genomic
DNA. Fig. 2 shows a Southern blot ofDNA from the starting
cell line and from one of the targeted cell lines after digestion
with four restriction enzymes. The EcoRI digest shows an
endogenous band of 7.3 kb (also present in DNA from the
starting cell line) and a band of 2.0 kb, which is the size
expected from a correctly targeted chromosome. The Bgl II
digest gives a 5.4-kb band (corresponding to the endogenous
locus) and the expected 6.5-kb band derived from a targeted
locus. The Pst I digest shows a 2.2-kb endogenous band and
a 1.95-kb band expected for targeting. The Sph I pattern is
also as expected: 20 kb for the endogenous locus and 4.7 kb
for the targeted locus. This and other blots were subsequently
hybridized to a probe specific for the neo gene. The results
demonstrated that the only copy of the targeting plasmid in
the ES cell genomes is at the targeted locus (data not shown).
Phenotypes. One of the three targeted ES cell lines was
used to generate chimeric animals by injection into host
blastocysts. Of seven chimeras tested, three males transmit-
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FIG. 1. Targeting construct and homologous recombination.
Line A represents the normal endogenous Hbbd bi locus. Line B
represents the linearized targeting plasmid. Line C represents the
targeted bl locus. A 1.1-kb fragment (NEO in open box) from
pMC1POLA (Stratagene) capable of conferring resistance to G418
was inserted at a BamHI (B) site in exon 2 of the bi gene. Exons of
the bi gene are shown as black boxes. Large X's denote regions
where crossing-over could occur within the homologous segments.
PCR primers are indicated by arrows. A fragment containing the tk
gene (TK in a hatched box) from herpes simplex virus 1 was inserted
both 5' and 3' ofthe homologous segments. A thin wavy line indicates
vector sequences. The probe for hybridization of Southern blots of
PCR-amplified fragments and of genomic DNA digests is shown as
a stippled box.
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FIG. 2. Southern blots ofDNA from the starting and targeted cell
lines. The blots of DNA from the starting cell line E14TG2a (S) and
a targeted cell line (T) after digestion with four enzymes. The location
of the probe used is shown in Fig. 1. Sizes of bands are given in kb.
being mated to C57BL/6J females. The F1 offspring that are
heterozygous for the disrupted bi gene (+/-) appear normal.
In contrast, homozygous mutants (-/-) obtained after mat-
ing heterozygotes are very pale and die either in utero close
to term or just after birth. Of five -/- mice that were alive
at birth and were cared for by their mothers, none survived
>4 hr. The phenotype of the mutant homozygotes is readily
apparent as a marked pallor at day 16.5 of gestation, the time
at which the mouse embryonic genes are no longer ex-
pressed, and the embryo becomes dependent on its adult
genes (1). The hematocrits of -/- mice at 18.5 days of
gestation are extremely low (8.3 ± 3.4%; n = 7), reflecting
their severe anemia. Heterozygotes have hematocrits (33 +
4.8%; n = 7) indistinguishable from normal homozygotes (34
+ 4.5%; n = 4).
The lethal thalassemia seen in our disruption homozygotes
is not detectably affected by genetic heterogeneity, asjudged
by observing the same phenotype in F2, F3, and F4 disruption
homozygotes derived from the F1 animals initially obtained
by breeding the strain 129-derived male chimeras to C57BL
females. (Each of these homozygotes has an essentially
random sampling of 129-derived and C57BL-derived alleles
at any locus at which these two inbred strains differ.) The
insensitivity ofthe disrupted mutant phenotype to this limited
amount of genetic heterogeniety is also illustrated by our
observing the same phenotype when the mutation was pre-
sent in otherwise completely inbred strain 129 animals.
Fig. 3 shows blood smears from normal/mutant heterozy-
gous (+/-) and homozygous mutant (-/-) embryos at 18.5
days of gestation. The mutant (-/-) smear shows charac-
teristics typical of severe thalassemia: few normally rounded
red cells, evidence of hypochromia, poikilocytosis, and pres-
ence of nucleated red blood cell precursors.
Fig. 4 shows a comparison ofthe hemoglobins produced by
normal (+/+), heterozygous (+/-), and mutant homozy-
gous (-/-) embryos at 18.5 days of gestation. The hemo-
globin produced by the -/- mice shows no detectable
protein corresponding to the bi gene, although the b2 gene is
clearly active.
Comparison with a Deletion Thalassemia in Mice. Some
features of the thalassemic phenotype of mice homozygous
for the insertionally disrupted bl gene (which we propose to
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FIG. 3. Blood smears. Smears of whole blood from embryos at 18.5 days of gestation from a normal/mutant heterozygote (/)(A) and
a mutant homozygote (-/-) (B) stained with Wright's stain.
call Hbb'h-2) are similar to those seen in the thalassemic mice
that result from homozygosity for a naturally arising 3709-bp
deletion of the bi gene (which was named Hbbth-h), in which
all of its coding regions and 5' regulatory sequences are
missing (3, 12). Both are small and pale at birth, have reduced
hematocrits, and have blood smears characteristic of
thalassemia. Like the disruption mutant, the phenotype ofthe
deletion homozygous animals is generally insensitive to ge-
netic background, as judged by finding essentially the same
phenotype in mice derived from crosses between mouse
strains DBA and C57BL, and in mice derived after back-
crossing to C57BL. However, the insertionally disrupted
gene is lethal in the homozygous state, whereas more than
half of the deletion homozygotes survive to adulthood (3).
Curcio et al. (13) have suggested that in the deletion
animals there is a "compensatory" increase of 3- to 4-fold in
hemoglobin tetramers containing b2-derived protein com-
pared to normal mice. The authors report that the ratio of
b2-derived mRNA to a-globin mRNA is increased from 0.2 in
normal animals to 0.3 in deletion homozygotes; thus, part of
the compensation is probably due to a relative increase in b2
mRNA levels. They also report that the ratio of b2-derived
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FIG. 4. Cellulose acetate electrophoresis ofmouse hemoglobins.
The bi genotypes of the animals from which the samples were
prepared are indicated, as are the positions of hemoglobins contain-
ing either bl- or b2-derived proteins.
polypeptide chain synthesis to a-globin polypeptide chain
synthesis is increased from 0.2 in normal animals to 0.75 in
the deletion homozygotes; thus another part of the compen-
sation must occur during the translation of the messages, and
the authors present evidence that this is likely due to com-
petition for translational factors.
Preliminary comparisons have been made in animals het-
erozygous for one of the mutant chromosomes and for a
normal Hbbs chromosome of the levels of b2 gene-derived
polypeptides from the Hbbd bl-deletion chromosome, and
from the Hbbd bl-disruption chromosome, and also from a
normal Hbbd chromosome (J. B. Whitney III, personal com-
munication). The b2 gene in the Hbbd bl-deletion chromo-
some produces 58.4% (±1.1%) as much protein as a normal
Hbbs chromosome with two genes (blS and b2s). The b2 gene
in the Hbbd bl-disruption chromosome produces 43.1%
(±2.5%). The b2 gene in a normal Hbbd chromosome pro-
duces 32.8% (±3.5%). These results are in accord with the
two mutant phenotypes, in that the amount of b2 product is
greater with the bl-deletion than with the bl-disruption
chromosome.
Comparison with Human Thalassemias. The different ef-
fects on b2-globin gene expression of deletion versus disrup-
tion of the bl gene are remarkably similar to the effects that
various mutations in the adult human ,B-globin gene have on
the neighboring adult ,3type globin gene, 8 (for reviews, see
refs. 14 and 15). In normal humans, adult hemoglobin con-
sists of 97-98% hemoglobin A (a2182) and 2-3% hemoglobin
A2 (a262). All ,3-thalassemic patients with normal 8-globin
genes have elevated levels of hemoglobin A2. Patients who
are heterozygotes for a point mutation or small deletion in the
,B3globin gene that does not remove its 5' regulatory se-
quences show hemoglobin A2 levels in the range of3.5-6.8%.
Patients heterozygous for deletional mutations that remove
part or all of the 5' regulatory sequences of the (-globin gene
have unusually high levels of hemoglobin A2 (7-12%). In one
study, by Codrington et al. (16), a direct comparison with the
mouse data is possible because the authors could distinguish
proteins derived from the 8 gene in cis and in trans to the
mutated ,B-globin gene. In a mutation removing the f-globin
promoter (a 1393-bp deletion), the expression of the 8 gene in
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FIG. 5. Model summarizing factors influencing expression of mouse adult ,3globin genes. Three chromosomes are identified by the status
of their respective bl genes. The deleted region is shown by parentheses ( ), and the insertionally disrupted bi gene is labeled bl*. Black
rectangles indicate the LCR, the bl, b2, and neo genes. The solid lines (not to scale) indicate chromosomal DNA. The dots indicate postulated
interactions between the LCR and promoters in the adult /-globin gene region.
cis was increased much more (5.5% oftotal hemoglobin) than
that of the gene in trans (2.5%). In contrast, a thalassemic
mutation not affecting the promoter (a frameshift mutation at
codon 47) increased the expression equally of both the cis
(2.4%) and trans (2.5%) 6-globin genes. The similarity of
effects that these various mutations in one adult f-globin
gene have on the levels of expression of the neighboring adult
,B-globin gene suggests that they are the consequence of the
same molecular mechanisms in humans and mice.
Expression in Cultured Cells. Related effects have also been
observed in gene-targeting experiments in which selectable
genes have been inserted into the human /-globin locus in
mouse erythroleukemia cells carrying a human chromosome
11. In two cases in which tests were made, expression of the
inserted gene was inducible by agents that normally induce
3-globin synthesis in mouse erythroleukemia cells (17, 18).
This result suggests that the selectable gene has fallen under
the influence of elements that normally control 3globin
synthesis.
Summary Model. Fig. 5 presents a model summarizing
factors that could account for the phenotypic differences
between the deletion (Hbb'h-I) and disruption (Hbb'h-2) ani-
mals, for the similar observations in humans, and for the
mouse erythroleukemia cell data. This model is based on
current views of the way in which the LCR controls expres-
sion of genes in the 83-globin gene cluster (4-7, 19, 20). The
LCR, which lies upstream of the ,-globin gene cluster, was
originally identified as five regions containing DNase I-hy-
persensitive sites, the sequences of which are highly con-
served in various mammalian species throughout evolution
(21, 22), including the mouse (23). The LCR is thought to
stimulate f3-globin expression as a result of its interaction
(probably mediated by proteins) with the promoters of spe-
cific f3globin genes. The LCR also has the ability to interact
with and stimulate nonglobin promoters, including a tk pro-
moter driving a neo gene (20). We suggest in our model that
deletion of the bi gene and its 5' regulatory sequences allows
the promoter of the b2 gene to interact with the LCR without
competition from the promoter of a bi gene. Transcription of
the b2 gene would thus be enhanced, and net synthesis of
b2-derived polypeptides would be increased. In contrast,
insertional disruption of the bi gene by homologous recom-
bination does not remove any promoter sequences; rather, it
inserts an additional promoter (the tk promoter driving the
neo gene). Thus, the b2 gene on the disrupted chromosome
has two promoters competing with it for the upstream LCR,
and its transcription is expected to be less than on the deletion
chromosome and, possibly, less than on the normal chromo-
some. In the gene-targeted mouse erythroleukemia cells,
interaction of the LCR with the promoter of the selectable
gene could explain the selectable gene having acquired the
ability to be induced.
Translational "compensation" may also be a factor (13). In
the deletion animals, b2-globin mRNA is the only f3-globin-
related mRNA competing with a-globin mRNAs for transla-
tional factors. In the insertional disruption animals, the
b2-derived mRNA also has to compete with mRNAs tran-
scribed from the bl and neo gene promoters, neither ofwhich
codes for a functional ,3-globin polypeptide. Such transla-
tional competition would further exacerbate the thalassemia
caused by the insertion relative to that caused by the deletion.
We stress that, in the absence of direct experiments, the
relative importances ofthe various factors summarized in the
model cannot be specified. Clearly, it will be necessary to
carry out a detailed analysis of the transcriptional efficacies
of the disrupted bi gene, the tk-driven neo gene, and the
unaltered b2 gene. The abundances and stabilities of their
mRNAs will likewise need to be determined to assess the
importance of translational competition. However, even in
the absence of these data it is apparent that at all these levels
the b2 gene on the deletion chromosome has an advantage
over the b2 gene on the insertionally disrupted chromosome.
Conclusion. The unexpected differences in the phenotypes
resulting from insertional disruption of the mouse bl-globin
gene (Hbbth-2) or deletion of the same gene (Hbbth-1) have
important implications for the control of expression of clus-
tered genes. They also indicate the need for caution when
interpreting the results of gene-disruption experiments. The
severely thalassemic animals that we have generated should
be of value in studies of somatic cell therapy and as a
background for breeding with human sickle transgenes.
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